Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.37 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314852 | 0.86 | ALDH1A1 (0.56) | HPGDALDH1A1TSHRSMN1; SMN2AVPR1A | |
| SCHEMBL12841365 | 0.81 | TSHR (0.62) | HPGDTSHRCYP17A1CYP3A4CYP19A1 | |
| SCHEMBL12841355 | 0.74 | TSHR (0.50) | HPGDTSHRCYP17A1CYP3A4CYP19A1 | |
| SCHEMBL316222 | 0.71 | BRD4 (0.69) | HPGDTSHRCYP17A1CYP3A4CYP19A1 | |
| SCHEMBL315346 | 0.70 | ALDH1A1 (0.40) | HPGDALDH1A1AVPR1AAVPR2 | |
| SCHEMBL315345 | 0.70 | ALDH1A1 (0.40) | HPGDALDH1A1AVPR1AAVPR2 | |
| SCHEMBL315344 | 0.70 | ALDH1A1 (0.40) | HPGDALDH1A1AVPR1AAVPR2 | |
| SCHEMBL315070 | 0.68 | ALDH1A1 (0.45) | HPGDALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL24167142 | 0.68 | GSK3B (0.44) | HPGDALDH1A1TSHRCYP3A4 | |
| SCHEMBL13002472 | 0.66 | TSHR (0.52) | HPGDTSHRCYP17A1CYP3A4CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | claimed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093240-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2322527-A1 | Triazole derivatives | Merck Patent GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306042-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2007079820-A1 | TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306042-A1 | Triazole Derivatives | TGFBR1, TGFBR2, SMAD3 | HPGD 2258/4885ALDH1A1 2295/4885TSHR 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.